Article Versions Notes

Galitzia A, Barabino L, Murru R, Caocci G, Greco M, Angioni G, Mulas O, Oppi S, Massidda S, Costa A, et al. Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine. Vaccines. 2022; 10(7):1162. https://doi.org/10.3390/vaccines10071162

Galitzia, Andrea, Luca Barabino, Roberta Murru, Giovanni Caocci, Marianna Greco, Giancarlo Angioni, Olga Mulas, Sara Oppi, Stefania Massidda, Alessandro Costa, and et al. 2022. "Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine" Vaccines 10, no. 7: 1162. https://doi.org/10.3390/vaccines10071162

Galitzia, A., Barabino, L., Murru, R., Caocci, G., Greco, M., Angioni, G., Mulas, O., Oppi, S., Massidda, S., Costa, A., & La Nasa, G. (2022). Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine. Vaccines, 10(7), 1162. https://doi.org/10.3390/vaccines10071162